On the nature of degenerative diseases and possible therapy: A hypothesis

Acta Myologica

Volumn 23, Issue 2, 2004, Pages 103-105

  Milder, Dan G ^a,b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b NONE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C3D RECEPTOR; FC RECEPTOR; GLATIRAMER; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE;

ALZHEIMER DISEASE; ANTIGEN PRESENTING CELL; ARTICLE; CELL DAMAGE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; DEGENERATIVE DISEASE; DENDRITE; HUMAN; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; MICROGLIA; MOTOR NEURON DISEASE; MULTIPLE SCLEROSIS; NERVE CELL NECROSIS; NONHUMAN; PARKINSON DISEASE; PRION DISEASE;

ANIMALS; COMPLEMENT C3D; DISEASE PROGRESSION; GAMMA-GLOBULINS; HUMANS; MICROGLIA; NEURODEGENERATIVE DISEASES;

EID: 9344258603     PISSN: 11282460     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Chen G, Goeddel DV. TNF-R1 signaling a beautiful pathway. Science 2002;296:1634-5.
2. Van Der Laan LJ, Ruuls SR, Weber KS, et al. Macrophage phagocytosis of myelin in vitro determined by flow cytometry: phagocytosis is mediated by Cr3 and induces production of tumour necrosis factor-alpha and nitric oxide. J Neuroimmunol 1996;70:145-52.
3. Fearon DT. The complement system and adaptive immunity. Seminars in Immunology 1998;10:355-61.
4. Dempsey PW, Allinson ME, Akkaraju S, et al. C3d of complement as a molecular adjuvant; bridging innate and acquired immunity. Science 1996;271:348-50.
5. Le W, Rowe D, Xie W, et al. Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J Neurosci 2001;21:8447-55.
6. He Y, Le WD, Appel SH. Role of Fc gamma receptors in nigral cell injury induced by Parkinson disease immunoglobulin injection into mouse substantia nigra. Experi Neurol 2002;176:322-7.
7. Mohamed HA, Mosier DR, Zou LL, et al. Immunoglobulin Fc gamma receptor promotes immunoglobulin uptake, immunoglobulin-mediated calcium increase, and neurotransmitter release in motor neurons. J of Neurosci Res 2002;69:110-16.
8. McGeer PL, McGeer EG, Kawamata T, et al. Reactions of the immune system in chronic degenerative neurological diseases. Can J Neurol Sci 1991;18 (Suppl. 3):376-9.
9. Yamada T, McGeer PL, McGee EG, Lewy bodies in Parkinson's disease are recognised by antibodies to 9D complement proteins. Acta Neuropathol 1992;84:100-4.
10. Hageman GS, Luthert PJ, Victor Chong NH, et al. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Progr Retinal Eye Res 2001;20:705-32.
11. Prineas JW, Kwon EE, Cho Es, et al. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 2001;50:646-57.
12. Milder DG. Partial and significant reversal of progressive visual and neurologic deficits in multiple sclerosis: a possible therapeutic effect. Clini Experi Ophthalmol 2002;30:363-6.
13. Milder DG. Immunomodulatory therapies and low dose Azathioprine reverse partially and significantly progressive visual and neurologic deficits in multiple sclerosis: further observations. Acta Myol 2002;21:144-50.
14. Hussien Y, Sanna A, Soderdstrom M, et al. Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis. J of Neuroimmunol 2001;121:102-10.
15. Markovic-Plese S, Bielekova B, Kadom N, et al. Longitudinal magnetic resonance imaging study on the effect of Azathioprine in relapsing-remitting multiple sclerosis refractory to the treatment with Interferon B-1b. Neurology 2003;60:1849-51.
16. Kaya Z, Afanasyeva M, Wang Y, et al. Contribution of the innate immune system to autoimmune myocarditis: a role for complement. Nature Immunol 2001;2:739-45.
17. Hanafusa T, Miyazaki A, Miyagawa J, et al. Examination of islets in the pancreas biopsy specimens from newly diagnosed type 1 (insulin-dependent) diabetic patients. Diabetologia 1990;33:105-11.
18. Basta M, Dalakas MC. High-dose Intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994;94:1729-35.